



## Symposium

### New antimalarials: from drug discovery to clinical trials

**December 19<sup>th</sup> 2022**

|               |                       |                 |   |
|---------------|-----------------------|-----------------|---|
| 9:00 – 9:20   | Organizers            |                 | Opening   |
| 9:20 – 9:50   | José Pedro Gil        | Karolinska      | Artemether/lumefantrine therapy is associated with <i>pfmdr-1</i> gene duplication in Africa  |
| 9:50 – 10:20  | Anna Caroline Aguiar  | Unifesp         | From the bench to the field: ex vivo evaluation of new compounds against <i>Plasmodium vivax</i> and <i>P. falciparum</i> field isolates              |
| 10:20 – 11:00 | Coffee Break          |                 |   |
| 11:00 – 11:30 | Roberto Moraes Barros | Unifesp         | Use of Nano-Luc expressing parasites in high-throughput screens for antimalarial drugs against <i>Plasmodium knowlesi</i> and <i>Plasmodium vivax</i> |
| 11:30 – 12:00 | Cornelis Winnips      | Novartis        | Ganaplacide/Lumefantrine-SDF, a next-generation treatment for acute malaria   |
| 12:00 – 13:30 | Lunch                 |                 |   |
| 13:30 – 14:00 | Lise Musset           | Pasteur Cayenne | Transmission and drug resistance capacities of <i>P. falciparum</i> in the Guiana Shield  |
| 14:00 – 14:30 | Leonardo J. Carvalho  | Fiocruz         | Adjuvant therapies for cerebral malaria based on recovery of vascular function  |
| 14:30 – 14:50 | Marcell Crispim       | ICB/USP         | The essential functions of isoprenoids as a tool for the discovery and potentiation of antimalarial compounds   |
| 14:50 – 15:40 | Coffee Break          |                 |   |
| 15:40 – 16:00 | Kim Williamson        | USUHS           | Targeting <i>P. falciparum</i> gametocytes to block malaria transmission  |
| 16:00 – 16:30 | Igor Mota R. de Moura | USP             | Discovery of inhibitors from Brazilian savana plants as lead compound candidates for malaria  |
| 16:30 – 17:00 | Luiz Carlos Dias      | Unicamp         | The MINDI Consortium: Drug Discovery for the most Neglected   |



**December 20<sup>th</sup> 2022**

|                     |                         |                      |   |
|---------------------|-------------------------|----------------------|---|
| 9:00 – 9:30         | Glaucius Oliva          | USP                  | Challenges and opportunities in drug discovery against infectious diseases  |
| 9:30 – 10:00        | Brice Campo             | MMV                  | Development of New Antimalarials focusing on <i>P.vivax</i> Liver Stage Hypnozoites   |
| 10:00 – 10:30       | Leyre Pernaute          | Karolinska           | DHA/Piperaquine post treatment prophylaxis and drug resistance markers in Africa  |
| <b>Coffee Break</b> |                         |                      |   |
| 11:00 – 11:30       | Pedro Cravo             | Nova Univ. of Lisbon | On the contribution of the rodent model <i>Plasmodium chabaudi</i> for understanding the genetics of drug resistance in malaria |
| 11:30 – 12:00       | David Fidock            | Columbia Univ.       | Genetic studies into <i>Plasmodium falciparum</i> determinants of resistance to first-line antimalarial drugs                   |
| 12:00 – 13:30       | <b>Lunch</b>            |                      |   |
| 13:30 – 14:00       | Taís Nobrega de Souza   | Karolinska           | Current progress in pharmacogenetics of antimalarials used for the treatment of <i>Plasmodium vivax</i> malaria                 |
| 14:00 – 14:30       | Leticia Tiburcio        | Columbia Univ.       | Looking into 4-aminoquinolines as multistage antimalarials  |
| 14:30 – 14:50       | Camila de Souza Barbosa | USP                  | Discovery of brussonol as a lead candidate for malaria  |
| 14:50 – 15:10       | Camila Fabbri           | Fiocruz              | Implementation of new strategies to investigate transmission blocking compounds against <i>P. vivax</i>                         |
| 15:10 – 15:30       | <b>Coffee Break</b>     |                      |   |
| 15:30 – 16:00       | Celia Garcia            | USP                  | <i>Plasmodium falciparum</i> signaling pathways as targets of antimalarial drugs  |
| 16:00 – 16:30       | Gustavo Cassiano        | Nova Univ. of Lisbon | Discovery of potent antimalarial 1,4-naphthoquinones identified from computational screening                                    |
| 16:30 – 17:00       | Dhelio Pereira          | CEPEM                | Antimalarials, the last two miles: clinical trial and implementation  |
| 17:00 – 17:10       | Organizers              |                      | Closing   |